The American Hospital Association appreciates the opportunity to work with the Centers for Medicare & Medicaid Services (CMS) on implementation of the No Surprises Act.
Letters
Throughout the year, the AHA comments on a vast number of proposed and interim final rules put forth by the federal regulatory agencies. In addition, AHA communicates with federal legislators to convey the hospital field's position on potential legislative changes that would impact patients and patient care. Below are the most recent letters from the AHA to these bodies.
Latest
AHA letter to Senator Kevin Cramer expressing support for the Travel Nursing Agency Transparency Study Act.
AHA comments on the Centers for Medicare & Medicaid Services’ Radiation Oncology (RO) Model proposed rule.
AHA provides feedback on the Food and Drug Administration
Safety and Landmark Advancements (FDASLA) Act (S.4348).
AHA letter to the Centers for Medicare & Medicaid Services regarding the FY 2023 IRF prospective payment system (PPS) proposed rule.
AHA letter to the Centers for Medicare & Medicaid Services regarding the FY 2023 IRF prospective payment system (PPS) proposed rule.
AHA comments on the Internal Revenue Service’s (IRS) proposed rule amending how employer coverage affordability would be measured for family members of employees.
The AHA urges the FTC to increase scrutiny on insurer-mandated white bagging policies, as well as the impact of PBM-negotiated rebates and other business practices on the 340B drug discount pricing program and overall drug prices and drug price increases.
AHA urges CMS to take swift action to hold Medicare Advantage (MA) plans accountable for inappropriately and illegally restricting beneficiary access to medically necessary care.
The AHA urges the Department of Justice to establish a task force to conduct False Claims Act investigations into commercial health insurance companies that are found to routinely deny patients access to services and deny payments to health care providers.